Roche Hldg Ltd Spons (RHHBY) 30.5300 $RHHBY Roche Gets

New Post Public Reply Private Reply Replies (0) Message Board

Aug 31, 2016 at 1:12 PM

Roche Hldg Ltd Spons (RHHBY) 30.5300 $RHHBY

Roche Gets FDA Nod for Emergency Use of Zika Virus Test
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 7:41AM CDT
Roche Holdings (RHHBY) announced that the FDA has issued an Emergency Use Authorization (EUA) for its LightMix Zika rRT-PCR Test.
ANIP: 59.49 (-1.37), CORT: 5.36 (-0.05), PCRX: 39.98 (-1.10)

FDA Advises Zika Test for All U.S. Blood: Will Hologic Gain?
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 7:37AM CDT
The recent FDA recommendation allowing Hologic???s (HOLX) Procleix assay to be one of the two tests to be used in the nationwide screening will boost its test revenue growth.
DGX: 82.62 (-0.92), IDXX: 112.04 (-1.02), HOLX: 38.31 (-0.15)

Roche Holding Set to Possibly Rebound After Yesterday's Selloff of 1.15%
Comtex SmarTrend(R) - Wed Aug 24, 3:17PM CDT
Roche Holding (NASDAQ:RHHBY) traded in a range yesterday that spanned from a low of $31.39 to a high of $31.68. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $31.50 on volume of 452,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Roche Launches Accu-Chek Blood Glucose Monitoring System
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 8:47AM CDT
The launch of new systems will help Roche (RHHBY) offset the sales decline in the diabetes care business due to pricing pressure in the U.S. and reimbursement issues
ANIP: 59.49 (-1.37), CORT: 5.36 (-0.05), PCRX: 39.98 (-1.10)

Puma (PBYI) Neratinib's Application Validated in EU, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 8:37AM CDT
Puma (PBYI) announced that its Marketing Authorization Application for neratinib has been validated by the European Medicines Agency.
ANIP: 59.49 (-1.37), PBYI: 58.70 (-0.57)

Cerulean (CERU) Kidney Cancer Drug Disappoints in Phase II
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 9:11AM CDT
Cerulean (CERU) announced disappointing top-line results from a phase II, study on CRLX101 for the treatment of patients with advanced RCC.
ANIP: 59.49 (-1.37), CERU: 1.03 (+0.02), ANIK: 47.22 (-0.23)

Epizyme Doses First Patient in Phase II Mesothelioma Study
Zacks Equity Research - Zacks Investment Research - Mon Aug 15, 8:25AM CDT
Epizyme (EPZM) dosed the first patient in a phase II study on tazemetostat for the treatment of adults with mesothelioma, characterized by BAP1 loss-of-function.
ADRO: 14.17 (+0.22), EPZM: 7.33 (-0.25), LLY: 77.58 (-0.19)

Epizyme (EPZM) Q2 Loss Lower than Expected, Costs to Rise
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 8:22AM CDT
Epizyme (EPZM) reported a loss of 49 cents per share in the second quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 50 cents.
GERN: 2.69 (unch), EPZM: 7.33 (-0.25), GSK: 43.32 (-0.04)

Celldex (CLDX) Posts Narrower Q2 Loss, Focus on Pipeline
Arpita Dutt - Zacks Investment Research - Tue Aug 09, 6:01AM CDT
While Celldex's (CLDX) Q2 loss was narrower-than-expected, focus remains primarily on the company's pipeline progress.
ANIP: 59.49 (-1.37), CLDX: 3.35 (-0.08), BMY: 57.05 (-0.19)

Roche Holding Set to Possibly Pullback After Yesterday's Rally of 1.33%
Comtex SmarTrend(R) - Fri Aug 05, 2:01PM CDT
Roche Holding (NASDAQ:RHHBY) traded in a range yesterday that spanned from a low of $31.83 to a high of $32.10. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $32.07 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Immune Design (IMDZ): Stock to Disappoint on Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 5:23PM CDT
Immune Design Corp. (IMDZ) is scheduled to report second-quarter 2016 results after the market closes on Aug 9.
IPXL: 24.16 (-0.26), IMDZ: 7.03 (+0.03), MRK: 62.68 (-0.03)

Exelixis (EXEL) Posts Narrower Loss in Q2, Beats on Revenues
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 2:52PM CDT
Exelixis, Inc. (EXEL) posted a second-quarter 2016 loss of 16 cents, narrower than both the Zacks Consensus Estimate of 27 cents and the year-ago loss of 22 cents
BIIB: 305.43 (-2.43), EXEL: 10.98 (-0.06)

What's in the Cards for Puma (PBYI) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 9:51AM CDT
Puma Biotechnology (PBYI) is expected to report second-quarter 2016 results on Aug 8. The company posted a negative surprise of 17.74% last quarter.
IPXL: 24.16 (-0.26), MYL: 42.07 (-0.68), PBYI: 58.70 (-0.57)

Prothena (PRTA) Reports Wider-than-Anticipated Loss in Q2
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 9:45AM CDT
Prothena (PRTA) reported a wider-than-expected loss of $1.18 per share in the second quarter of 2016.
ZTS: 50.70 (-0.05), ANIP: 59.49 (-1.37), PRTA: 50.00 (-0.52)

What's in Store for Epizyme (EPZM) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 9:43AM CDT
Epizyme (EPZM) is schedule to report second-quarter 2016 results on Aug 9 before the opening bell.
IPXL: 24.16 (-0.26), MYL: 42.07 (-0.68), EPZM: 7.33 (-0.25)

Will ImmunoGen (IMGN) Disappoint Again on Q4 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 5:30PM CDT
ImmunoGen (IMGN), which is set to report its fourth-quarter fiscal 2016 results on Aug 4, had recorded a negative surprise of 23.33% last quarter.
BMRN: 94.41 (-0.54), IMGN: 2.85 (-0.03)

Exelixis (EXEL) Q2 Earnings Preview: Stock Likely to Gain?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 10:55AM CDT
Exelixis, Inc. (EXEL) is scheduled to report second-quarter 2016 results on Aug 3 after the market closes.
IPXL: 24.16 (-0.26), IRWD: 13.22 (-0.20), EXEL: 10.98 (-0.06)

Epizyme Teams Up with Roche's Genentech for Tazemetostat
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 7:32AM CDT
Epizyme (EPZM) announced that it has entered into a collaboration agreement with Roche's (RHHBY) Genentech to evaluate tazemetostat, in combination Tecentriq.
ANIP: 59.49 (-1.37), PFE: 34.66 (-0.22), EPZM: 7.33 (-0.25)

Roche Presents Encouraging Data on Actemra and Tecentriq
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 3:49PM CDT
Roche Holding AG (RHHBY) announced positive results from the phase III study, GiACTA, on arthritis drug, Actemra/RoActemra.
PFE: 34.66 (-0.22), BMY: 57.05 (-0.19), EXEL: 10.98 (-0.06)

Phase III Study Shows Genentech's Actemra(R) (tocilizumab) Maintained Steroid-Free Remission in People With Giant Cell Arteritis (GCA)
BusinessWire - Mon Jun 06, 11:53AM CDT
--There have been no new treatments for GCA in more than 50 years

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fuse Oncology Showcases New iRT Workflow at ASTRO

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Cut Winter Heating Costs with Townsend's Rebate Help

Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...

IASO's FUCASO Shows Robust Results in 2026 Study

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Quay Shines in 2026 Prescription Sunglasses Lineup

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

China Southern Airlines Marks 70th Anniversary in NYC

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

Endurance Energy's Modular Tech Revs Up Southeast Asia

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...

AST SpaceMobile Faces Class Action Over Misstatements

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...

Farm Aid 2026: A Resilient Tribute to Family Farmers

Shining a Light on Essential Family Farmers Every year, thousands gather for Farm Aid to back the unsung heroes who put food on our plates. In 2026, the scene shifted to the amphitheater at Virginia Beach, where an epic lineup of music took stage not just to entertain but to underline a critical issue—family farmers are fighting for survival. These folks aren't merely...

Leo Cancer Care's Upright Radiotherapy Milestone

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...